Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02960022 · ClinicalTrials.gov registry record · Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
A Phase 2 study of Prostate Cancer, sponsored by Astellas Pharma Global Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 900
- Enrollment target
- 20
- Study locations
NCT02960022 is a Phase 2 study of Prostate Cancer that is actively recruiting participants, run by Astellas Pharma Global Development. The registered enrollment target is 900 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (48% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT02960022, a Phase 2 study of Prostate Cancer, is actively recruiting participants, sponsored by Astellas Pharma Global Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 900 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, the primary analysis or the study specified evaluation period.
Conditions Studied
Interventions
- DRUG enzalutamide
- DRUG abiraterone acetate
- DRUG prednisone
- DRUG Leuprolide acetate
Study Locations (20)
California
- Site US10040 - Los Angeles
- Site US10009 - Los Angeles
- Site US10067 - Orange
- Site US10008 - San Bernardino
- Site US10042 - San Diego
- Site US10028 - Stanford
Colorado
- Site US10001 - Aurora
- Site US10017 - Denver
Florida
- Site US10049 - Daytona Beach
- Site US10048 - Jacksonville
Illinois
- Site US10002 - Chicago
- Springfield Clinic, LLP - Springfield
Kansas
- University of Kansas Medical Center - Kansas City
- Site US10066 - Lenexa
Alaska
- Site US10052 - Anchorage
Arizona
- Site US10011 - Tucson
District of Columbia
- Site US10050 - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2016-12-22 |
| Est. Completion | 2029-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02960022
The ClinicalTrials.gov registry entry for NCT02960022 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (48% higher). The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which enzalutamide is the first listed.
NCT02960022 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT02960022 about?
NCT02960022 is a clinical study titled "A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study". The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at ...
What is the current status of trial NCT02960022?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 900 participants. The study started on 2016-12-22. Estimated completion is 2029-07-31.
What conditions does trial NCT02960022 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT02960022?
The interventions under investigation include: enzalutamide (DRUG), abiraterone acetate (DRUG), prednisone (DRUG), Leuprolide acetate (DRUG).
Who is sponsoring clinical trial NCT02960022?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02960022 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
-
Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.